2018 FDA Tides Harvest

Danah Al Shaer; Othman Al Musaimi; Fernando Albericio; Beatriz  G. de la Torre

doi:10.3390/ph12020052

Pharmaceuticals (Apr 2019)

2018 FDA Tides Harvest

Danah Al Shaer,
Othman Al Musaimi,
Fernando Albericio,
Beatriz G. de la Torre

Affiliations

Danah Al Shaer: KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
Othman Al Musaimi: KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
Fernando Albericio: School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa
Beatriz G. de la Torre: KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa

DOI: https://doi.org/10.3390/ph12020052
Journal volume & issue: Vol. 12, no. 2
p. 52

Abstract

Read online

In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.

Published in Pharmaceuticals

ISSN: 1424-8247 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Pharmacy and materia medica
Website: http://www.mdpi.com/journal/pharmaceuticals/

About the journal

Abstract

Keywords